Skip to content
thestock.space

On 6 Nov 2026, Cipla was priced at ₹1,411.00, or 39.4× trailing earnings, against an industry P/E of 28.7×. Sales and net profit grew 7.2% and 11% a year over 3 years, with ROCE of 15% and ROE of 8.3%. It carries very little debt, and its dividend yield is 0.9%. It is a large-cap company with a market cap of ₹1.1 lakh crore, ranked 7th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 6.6% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹1,387.00
Day high
₹1,411.00
Day low
₹1,382.00
Prev. close
₹1,404.10
Volume
15.7 L

Health check

2 fair · 4 to check
  • ReturnsBehind

    −6.6% over a year, better than 0 of 7 peers.

  • Price tagPricier

    P/E 39.4 vs industry 28.7.

  • GrowthSlow

    Sales +7.2%, profit +11.5% a year over 3 years.

  • ProfitabilityAverage

    ROCE 14.9% vs peer median 17.9%.

  • Balance sheetFair

    Practically debt-free, Piotroski 4 of 9.

  • Red flags2 to check

    Quarterly profit down 35.0% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Large cap

₹1.1L Cr, #7 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹27,989 Cr · profit ₹2,897 Cr
Market cap
₹1.1L Cr
Large cap
P/E
39.4
Industry 28.7
Price to book
3.22
Peers 5.97
Dividend yield
0.92%
ROE
8.3%
Peers 14.7%
ROCE
14.9%
Peers 17.9%
Debt to equity
0.02
Debt ₹699 Cr
EPS (TTM)
₹35.84
Face value ₹2
OPM (TTM)
17.3%
Net margin 10.4%
Sales growth
−1.1%
Latest quarter vs a year ago
Profit growth
−35.0%
Latest quarter vs a year ago
Price to sales
4.07
EV/EBITDA 22.6

Strengths and risks

Strengths

  • Practically debt-free.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Quarterly profit down 35.0% on a year ago.
  • Quarterly sales down 1.1% on a year ago.

Derived automatically from reported figures. Not a recommendation.

About Cipla

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid…

Headquarters
Mumbai
Employees
31,369
Sector
Healthcare
ISIN
INE059A01026
Website
cipla.com

Price range

52 weeks

₹1,165.70₹1,539.70

Today

₹1,382.00₹1,411.00
Avg volume (3M)
10 L
1-year return
minus 6.6%
From 52-week high
minus 8.4%

Analyst consensus

36 analysts
BuyMean target ₹1,507.31 plus 6.8%

Target range, with today’s price

Low ₹1,214.00High ₹1,800.00

Next results expected around 21 Jan 2027

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
MANKINDMankind Pharma2,540.00plus 0.87%1,04,91346.85.9713.7%13.6%26.5%17.7%14.3%0.00%plus 6.3%
Median of 7 peers–0.85%1,26,43346.85.9717.9%14.7%28.2%11.0%12.1%0.29%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Dec 25Mar 26Jun 26Sep 26
6,8376,9636,4647,0777,368
5,0595,7085,4675,8855,980
1,7781,2559971,1921,388
26.0%18.0%15.4%16.8%18.8%
259206148211151
14.11413.11716.7
253278383304345
–−276−42––
1,7708937071,0821,177
27.0%24.5%22.2%27.3%27.2%
1,298676555789878
16.068.366.869.7610.85

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+7.2%
Profit CAGR 3Y
+11.5%
EPS CAGR 3Y
+11.4%
ROE
8.3%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
22,47325,44727,14527,712
–+13.2%+6.7%+2.1%
17,43619,02720,00621,783
5,0376,4207,1405,929
22.4%25.2%26.3%21.4%
77.7383292326
94.671.14448.2
1,0191,0519951,084
37.421.2429100
4,0385,7026,8215,224
29.8%27.1%22.4%25.9%
2,8024,1225,2733,879
–+47.1%+27.9%minus 26.4%
34.6951.0165.2448.00

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
161161162162
23,24626,54531,03234,270
803559438614
5,2525,4525,7557,450
29,46332,71837,38742,496
5,8836,1716,7057,983
8921,1021,4431,943
4839236701,510
6,2637,77910,60910,028
15,94316,74317,95921,032
29,46332,71837,38742,496

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
3,2384,1345,0053,940
−2,389−2,988−3,691−2,326
−958−1,200−1,293−1,234
−109−54.621.1380
−1,183−1,349−1,548−3,079
2,0552,7853,457861
−404−686−1,050−1,292

Shareholding pattern

Source: NSE filings
29.2%
promoters
  • Promoters29.21%
  • Public70.79%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202629.21%70.79%0.00
30 Jun 202629.21%70.79%0.00
31 Mar 202629.21%70.79%0.00
31 Dec 202529.21%70.79%0.00
30 Sep 202529.21%70.79%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you